Articles tagged "Non-invasive diagnosis"

2018 American Transplant Congress
Kidney Transplantation is Associated with Decreasing Native T1 Time: A Cardiac Magnetic Resonance Study
M. Contti,¹ L. de Andrade,¹ H. Nga,¹ M. Valiatti,¹ H. Takase,¹ A. Bravin,¹ A. Mauricio,² M. Barbosa.³
¹Internal Medicine, Botucatu Medical School, Botucatu, Sao Paulo, Brazil; ²Radiology, Heart Institute of the Clinics Hospital at the Faculty of Medicine, University of São Paulo, São Paulo, Brazil; ³Radiology, Centro Avançado de Radiologia e Diagnóstico por Imagem, Presidente Prudente, Sao Paulo, Brazil.
Patients with stage 5 chronic kidney disease (CKD) have high rate of cardiovascular death. Kidney transplantantion, on the other hand, is associated with lower cardiovascular…
2018 American Transplant Congress
Renal Allograft Cortical Perfusion Quantification by 3D-Arterial Spin Labeling Could Be Used to Identify Subclinical Antibody-Mediated Rejection
W. Wang,¹ J. Wen,² F. Xu,² Y. Yu,³ L. Zhang,³ Z. Liu.²
¹Nanjing Medical University, Jinling School of Medicine, Nanjing, China; ²Jinling Hospital, Nanjing University School of Medicine, National Clinical Research Center of Kidney Diseases, Nanjing, China; ³Department of Medical Imaging, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Background: Antibody-mediated rejection (AMR) is now the most principal post-surgical complication complicating allograft long-term survival. Therefore, its early detection before serum creatinine rises/estimated glomerular filtration…
2018 American Transplant Congress
The Efficacy of Laser Speckle Flowgraphy Device for Intraoperative Evaluation of Renal Blood Flow after Reperfusion
M. Muramatsu,¹ Y. Itabashi,¹ Y. Takahashi,² K. Sakurabayashi,¹ T. Mizutani,¹ Y. Hyodo,¹ Y. Hamasaki,² T. Kawamura,¹ K. Sakai,¹ S. Shishido.^1,2
¹Nephrology, Toho University Faculty of Medicine, Tokyo, Japan; ²Pediatric Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.
Purpose:Laser speckle flowgraphy (LSFG) is a device to monitor cutaneous and ocular fundus blood flow. However, there is no report that the device was used…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.
J. Bromberg,¹ D. Brennan,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Yee,⁴ J. Sninsky,⁴ R. Bloom.⁵
¹University of Maryland, Baltimiore, MD; ²Washington University, St. Louis, MO; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the circulating blood of transplant recipients has shown promise as a non-invasive biomarker of acute rejection. This analysis was…
2017 American Transplant Congress
Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts.
K. Keslar,¹ A. Zmijewska,² J. Chen,² K. Newell,³ P. Heeger,⁴ R. Mannon,² R. Fairchild.¹
¹Department of Immunology, Cleveland Clinic, Cleveland, OH; ²Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL; ³Department of Surgery, Emory University, Atlanta, GA; ⁴Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY
A major goal of the Clinical Trials in Organ Transplantation (CTOT) studies is the identification of biomarkers that predict or diagnose acute graft rejection in…
2017 American Transplant Congress
Non-Invasive Detection of Rejection with ImmunoPET Imaging.
D. Mathews,¹ K. Lindsay,² P. Santangelo,² Y. Dong,¹ J. Tso,³ A. Adams.¹
¹Department of Surgery, Emory University, Atlanta, GA; ²Department of Biomedical Engineering, Georgia Tech, Atlanta, GA; ³JN Biosciences LLC, Mountain View, CA
Current approaches to detect and diagnose rejection are retrospective and/or invasive. These methods assess the extent of end organ damage by insensitive and non-specific measures…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Correlates with Antibody-Mediated Rejection in Kidney Allografts.
R. Bloom,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Sninsky,⁴ J. Yee,⁴ D. Brennan.⁵
¹University of Pennsylvania, Philadelphia, PA; ²University of Maryland, Baltimore, MD; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵Washington University, St. Louis, MO
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may enable more frequent, quantitative, and safer assessment of allograft rejection and…
2017 American Transplant Congress
The Role of Urinary Chemokines in Distinguishing Causes of Renal Allograft Dysfunction.
S. Chong,¹ R. Fernando,² M. Harber,¹ C. Magee.¹
¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom; ²Anthony Nolan Laboratories, Royal Free Hospital, London, United Kingdom
The aetiology of renal transplant dysfunction is varied, and diagnosis often relies upon transplant biopsy, an invasive procedure that carries significant risk. Availability of a…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.
D. Brennan,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ J. Sninsky,⁴ R. Woodward,⁴ J. Yee,⁴ R. Bloom.⁵
¹Washington University, St. Louis, MO; ²University of Maryland, Baltimore, MD; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) has shown promise as a biomarker in identification of allograft rejection. Here we report on the changes in dd-cfDNA prior…
2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹
¹University of Colorado, Aurora, CO; ²Baylor University Medical Center, Dallas, TX; ³Gilead Sciences, Inc., Foster City, CA.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…